All In Biotech

Drug Trial Radar · NCT02226588

Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt

Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in El Beheira Governorate, Egypt

Last checked: Nov 20, 2026Latest source record: Feb 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,827 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,827

Actual

Start

Oct 2014

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
Gynuity Health ProjectsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health and Population, Egypt; University of Alexandria; El Galaa Teaching Hospital
First posted
Aug 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to compare two community-level strategies: either selective, early administration of 800 mcg sublingual misoprostol to women for secondary prevention of postpartum hemorrhage (PPH) or universal use of 600 mcg oral misoprostol at the time of delivery for prophylaxis of PPH. The significance of this cluster randomized non-inferiority trial is its potential to inform service delivery programs on clinical outcomes, program feasibility, cost, and acceptability of two different community models of PPH care using misoprostol.1. The study hypothesizes that a service delivery model that administers misoprostol for secondary prevention is non-inferior to a model that administers misoprostol for universal prophylaxis.

Conditions

  • Postpartum Hemorrhage

Interventions

  • MisoprostolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean drop in pre- to post-delivery hemoglobin levelTime frame: Pre-delivery hemoglobin will be measured during a third trimester antenatal care visit or during early labor. Post-delivery hemoglbin will be measured 2 to 4 days after delivery of the baby.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Primary Health Care Units

    Damanhur, El Beheira, Egypt

  • Primary Health Care Units

    Kafr El Dawar, El Beheira, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.